

Researchers develop antibody-targeted treatment for recurrent small-cell lung cancer

4 March 2014

Researchers at Norris Cotton Cancer Center have found an antibody that may be used in future treatments for recurrent small-cell lung cancer, which currently has no effective therapy.

The mouse monoclonal antibody they have developed, MAG-1, targets the ProAVP surface marker. When given alone, it significantly slows the growth of tumor xenografts of human recurrent small-cell [lung cancer](#) in mice. The study, "Growth Impairment of Small-Cell Cancer by Targeting Pro-Vasopressin with MAG-1 Antibody," was recently published online in *Frontiers in Oncology*.

"We are developing methods of antibody-targeted treatment for recurrent small-cell lung cancer," said lead author William G. North, PhD, professor of Physiology at the Geisel School of Medicine at Dartmouth and a member of the Norris Cotton Cancer Center. "Targeting with a humanized MAG-1 can likely be effective, especially when given in combination with chemotherapy, for treating a deadly disease for which there is no [effective therapy](#)."

North says his group has already generated a human chimeric form of MAG-1 that is equally effective as mouse MAG-1, and they are now generating a humanized form for use in patients.

Provided by The Geisel School of Medicine at Dartmouth

APA citation: Researchers develop antibody-targeted treatment for recurrent small-cell lung cancer (2014, March 4) retrieved 16 June 2021 from <https://medicalxpress.com/news/2014-03-antibody-targeted-treatment-recurrent-small-cell-lung.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.